Liver diseases markedly contribute to the global burden of mortality and morbidity. The pathogenesis of alcohol- and non-alcohol-induced liver diseases is complex, and many factors have been described to contribute to the progressive loss of liver functions, including the over-generation of reactive oxygen species. Glutathione (GSH) is the most...
-
2016 (v1)PublicationUploaded on: April 14, 2023
-
2016 (v1)Publication
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is the second cause of death due to malignancy in the world. The treatment of HCC is complex and includes potentially curative and palliative approaches. However, both curative and palliative treatments for HCC are often associated with a not-completely favorable...
Uploaded on: April 14, 2023 -
2016 (v1)Publication
Curative treatments, including liver transplantation, surgical resection and percutaneous treatments, are the recommended therapies in BCLC-0 (Barcelona Clinic of Liver Cancer) or BCLC-A hepatocellular carcinoma (HCC). This review provides an overview of some issues of clinical importance concerning curative treatments in HCC.
Uploaded on: April 14, 2023 -
2021 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2018 (v1)Publication
Hepatocellular carcinoma is associated with several chronic liver diseases, especially chronic hepatitis B virus, hepatitis C virus, and alcoholism. It is increasingly appreciated that obesity/metabolic syndrome is also associated with chronic liver disease and subsequent hepatocellular carcinoma.
Uploaded on: April 14, 2023 -
2019 (v1)Publication
Despite progress in our understanding of the biology of hepatocellular carcinoma (HCC), this tumour remains difficult-to-cure for several reasons, starting from the particular disease environment where it arises-advanced chronic liver disease-to its heterogeneous clinical and biological behaviour. The advent, and good results, of immunotherapy...
Uploaded on: April 14, 2023 -
2018 (v1)Publication
Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database...
Uploaded on: April 14, 2023 -
2021 (v1)Publication
Hepatocellular carcinoma prognosis depends on both liver and tumor determinants, especially on maximum tumor diameter, multifocality, and presence of portal vein thrombosis, despite apparently complete tumor removal by resection or liver transplantation.
Uploaded on: April 14, 2023 -
2022 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2021 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2023 (v1)Publication
Background and Aims: Hepatocellular carcinoma (HCC) recurrence is common in patients treated with liver resection (LR). In this study, we aimed to evaluate the incidence and preoperative predictors of non-transplantable recurrence in patients with single HCC <= 5 cm treated with frontline LR.Methods: From the Italian Liver Cancer (ITA. LI.CA)...
Uploaded on: July 3, 2024 -
2019 (v1)Publication
The Italian Liver Cancer (ITA.LI.CA) prognostic system for patients with hepatocellular carcinoma (HCC) has recently been proposed and validated. We sought to explore the relationship among the ITA.LI.CA prognostic variables (i.e., tumor stage, functional score based on performance status and Child-Pugh score, and alpha-fetoprotein), treatment...
Uploaded on: April 14, 2023 -
2021 (v1)Publication
Epidemiology of hepatocellular carcinoma (HCC) is changing in most areas of the world. This study aimed at updating the changing scenario of etiology, clinical presentation, management and prognosis of HCC in Italy during the last 15 years.
Uploaded on: March 27, 2023 -
2017 (v1)Publication
A major problem in assessing the long-term outcome of HCV-infected cirrhotic patients with successfully treated Barcelona Clinic Liver Cancer (BCLC) A hepatocellular carcinoma (HCC) arises from the lack of models accounting for early changes during follow-up.
Uploaded on: April 14, 2023 -
2018 (v1)Publication
The Barcelona Clinic Liver Cancer advanced stage (BCLC C) of hepatocellular carcinoma (HCC) includes a heterogeneous population, where sorafenib alone is the recommended treatment. In this study our aim was to assess treatment and overall survival (OS) of BCLC C patients sub-classified according to clinical features (Performance Status [PS],...
Uploaded on: April 14, 2023